TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A randomized trial in 40 primary care clinics in Jamaica and Colombia found that patients offered a single-pill combination strategy had better blood pressure control than those receiving usual care. The results were presented at the 2026 American Heart Association Scientific Sessions and published in JAMA; longer-term effects on major health outcomes remain to be studied.
A four-year randomized trial in Jamaica and Colombia found that patients with uncontrolled hypertension had better blood pressure control when offered a strategy based on a single pill combining two or three medicines than when treated with usual care. The findings were presented at the 2026 American Heart Association Scientific Sessions and published in JAMA, adding long-term evidence for an approach already recommended in treatment guidelines.
The Caribbean and South American Team-Based Strategy to Control Hypertension (CATCH) trial enrolled 1,706 patients at 40 primary care clinics. Clinics were assigned to provide either usual treatment, mainly “stepped care,” or the single-pill strategy. In stepped care, patients generally start with one blood pressure medicine, with clinicians increasing doses or adding medicines if blood pressure remains high.
At clinics using the single-pill strategy, patients received a pill combining two or three antihypertensive medicines. The program also included nurse instruction on home blood pressure measurement, study-supplied monitoring equipment and health coaching focused on taking medication as prescribed. The comparison was therefore between care strategies, not just between pills with different packaging.
After 18 months, average systolic blood pressure—the top number in a reading—had fallen by about 19 points in the single-pill group, compared with 9 points in the usual-care group. Nearly 70% of patients in the single-pill group met the trial’s target of below 130/80 mm Hg, versus 29% in the standard-care group. Six months after the trial ended, 75% of patients in the intervention group were still receiving the combination treatment through insurance or government programs and had maintained better control, the report said.
Why the Single-Pill Results Matter
High blood pressure is a major preventable risk factor for cardiovascular disease, stroke and chronic kidney disease, among other conditions. Yet control remains limited: the source report cites estimates that blood pressure is controlled in 22.5% of U.S. patients with hypertension and 13.6% in low- and middle-income countries. Those figures describe overall control, not the results of this trial.
A simpler regimen may help address one barrier to treatment: managing several separate medicines. The CATCH results also suggest that a supported single-pill program can be maintained after a trial intervention ends, at least for many participants in these settings. That could matter to health systems seeking practical ways to improve control, although the study does not establish that the approach will produce the same results in every country, clinic or patient group.
Trial co-leader Jiang He of UT Southwestern Medical Center said the findings provide evidence for physicians considering the treatment in the United States and elsewhere. The study measured blood pressure control and treatment continuation; it was not reported as showing fewer heart attacks, strokes or deaths.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms up to 1875 ft², Quiet 27 dB Operation, AHAM VERIFIDE Certified, Air Quality Monitor,
Blueair Blue Pure 211i Max Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
How CATCH Tested the Strategy
Guidelines in the United States and internationally recommend single-pill combinations as a preferred treatment strategy for many people with hypertension. Earlier trials had found that combination pills could lower blood pressure more quickly than multi-pill regimens, but many lasted only a few weeks. The CATCH study was designed to add evidence on longer-term effectiveness and implementation in primary care settings in Jamaica and Colombia.
The trial lasted four years, including recruitment, and was funded by the National Heart, Lung, and Blood Institute, part of the U.S. National Institutes of Health. The study was co-led by researchers from UT Southwestern and colleagues in Colombia and Jamaica. The findings were released alongside the scientific meeting presentation and publication in JAMA in November 2026.
The report says only about 10% of U.S. patients with hypertension receive single-pill combination therapy. It attributes clinicians’ limited use in part to unfamiliarity and a shortage of large, long-term trial evidence. The CATCH findings address duration and care delivery, but do not by themselves resolve every question about adoption.
“Our study demonstrated that a single-pill combination provided an effective, implementable, scalable, and sustainable approach for hypertension control in low- and middle-income countries.”
— Jiang He, M.D., M.S., Ph.D., co-leader of the trial and a UT Southwestern researcher
Questions Beyond Blood Pressure
The reported results show differences in blood pressure control, but the source material does not provide evidence that the strategy reduced heart attacks, strokes, kidney disease or deaths. The authors say more large clinical trials are needed to assess such clinical outcomes. The report also does not give detailed results on adverse effects, costs or whether the same level of benefit would occur outside the participating clinics.
Because the intervention combined medication with home monitoring and health coaching, the findings do not isolate how much of the improvement came from the single pill itself versus the broader team-based support. The reported six-month follow-up offers evidence of continued treatment for many participants, but it does not establish how long that continuation or improved control will persist.
Further Trials and Wider Use
The next evidence needed, according to the researchers, is larger clinical trials that examine whether single-pill combination strategies affect major health outcomes as well as blood pressure readings. Such research could help clinicians and patients weigh the benefits, risks and practical costs of wider use.
For now, the findings add long-term trial evidence to existing guideline recommendations. The study authors say the results may inform care in the United States and beyond, while questions about implementation in other health systems and lasting effects remain open. The source material does not identify a specific next trial or timetable.
Key Questions
What did the CATCH trial find?
At 18 months, the single-pill strategy group had an average systolic blood pressure reduction of about 19 points, compared with 9 points under usual care. Nearly 70% of the intervention group met the trial’s below-130/80 mm Hg target, compared with 29% of the standard-care group.
What was in the single pill?
The intervention used a pill combining two or three antihypertensive medicines. It was delivered with nurse-led home blood pressure monitoring support and health coaching on medication adherence.
Where and when was the study conducted?
The trial enrolled 1,706 patients at 40 primary care clinics in Jamaica and Colombia. Its results were presented at the 2026 American Heart Association Scientific Sessions and published in JAMA in November 2026.
Did the trial show fewer heart attacks or strokes?
The reported findings concern blood pressure control and continued treatment. The source material does not report that the trial demonstrated fewer heart attacks, strokes or deaths; the researchers called for more trials measuring clinical outcomes.
Does this mean every patient should switch to a combination pill?
No. The study compared care strategies in specific clinics and does not establish that one regimen is suitable for every patient. Treatment choices should be discussed with a qualified health professional.
Source: news-medical.net
